Medtronic (NYSE:MDT) said this month that it won approval for a change to its problematic SynchroMed II implantable drug infusion pump designed to address motor shaft wear issues.
The Fridley, Minn.-based medical device titan said the change is aimed at improving the long-term rate of non-recoverable motor stall in the SynchroMed II devices, estimating that pump survivability rates at six years for stalled pumps to be 97.3%2 with on-label drugs and 91.1%2 with off-label drugs.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic retools SynchroMed II infusion pump appeared first on MassDevice.
from MassDevice http://ift.tt/2juRx7S
Cap comentari:
Publica un comentari a l'entrada